ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 1179.5 | 1074.6 | 871.6 |
| Other income | 16.4 | 9.7 | 7.1 |
| Total income | 1195.9 | 1084.3 | 878.7 |
| Profit before exceptional items & tax | 56.6 | 65.7 | 113.7 |
| Exceptional items | 0.0 | -10.9 | 0.0 |
| Profit before tax | 56.6 | 54.8 | 113.7 |
| Net profit | 37.4 | 33.1 | 85.0 |
| Operating margin | 4.7% | 5.1% | 12.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -56.00% |
|---|---|
| Net profit, quarter on quarter | +13.00% |
| Revenue, year on year | +35.30% |
| Operating profit, year on year | -73.00% |
| Operating profit, quarter on quarter | -10.30% |
NSE results filing, NSE: KIMS. Figures extracted from the filing.
Krishna Institute of Medical Sciences Ltd: key numbers
- Share price
- ₹722.00
- Market cap
- ₹30,324 Cr
- Revenue (annual)
- ₹3,905 Cr
- Net profit (annual)
- ₹241.4 Cr
- P/E (TTM)
- 142.8×Sector 54.5×
- Promoter holding
- 32.66%+0.16% QoQ
- FII holding
- 15.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krishna Institute of Medical Sciences Ltd
All →Krishna Institute of Medical Sciences Earnings Call Transcript: Key Takeaways
KIMS delivered strong revenue growth led by Kondapur's rapid ramp-up, despite temporary margin compression from new oncology programs.
Krishna Institute of Medical Sciences Other Announcement
KIMS's CARE Ratings monitoring report shows ₹1,311.81 crore of the ₹1,476.45 crore QIP proceeds utilised till Q2 FY27. No deviation from the stated objects was reported.
Krishna Institute of Medical Sciences Management Change
KIMS re-appointed Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as CMD, and Ms. Dandamudi Anitha as Whole-time Director. Terms start in 2027.
- Execution
- 5 years
Krishna Institute of Medical Sciences Investor Presentation: Key Takeaways
Q2 FY27 total revenue Rs13,630 Mn (+41.3% YoY), EBITDA Rs2,789 Mn (20.5% margin), PAT Rs757 Mn (+5.1% YoY). Expansion via 700+ beds planned.
Krishna Institute of Medical Sciences Results Update
KIMS reported Q2 FY27 consolidated revenue of Rs 1,363 Crore, up 41.3% YoY, with PAT of Rs 76 Crore. EBITDA rose 34% YoY to Rs 279 Crore.
Krishna Institute of Medical Sciences Q2 FY27 Results: Net Profit ₹74.6 Cr, Up 3.6% YoY
Krishna Institute of Medical Sciences Ltd reported revenue from operations of ₹1,344 Cr (+39.9% YoY) and net profit of ₹74.6 Cr (+3.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹74.6 Cr · +3.6% YoY